We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+18.68%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$6.69B
AUM Growth
+$682M
Cap. Flow
-$395M
Cap. Flow %
-5.9%
Top 10 Hldgs %
54.02%
Holding
678
New
246
Increased
85
Reduced
72
Closed
235

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$85.8M
2
INDV icon
Indivior Pharmaceuticals
INDV
+$59.6M
3
BCAX
Bicara Therapeutics
BCAX
+$45.8M
4
MRUS
Merus
MRUS
+$34.4M
5
VTRS icon
Viatris
VTRS
+$30M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$102M
2
SGRY icon
Surgery Partners
SGRY
+$86.4M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$53.7M
4
IART icon
Integra LifeSciences
IART
+$42.8M
5
BNTX icon
BioNTech
BNTX
+$38.6M

Sector Composition

Rank Sector Weight
1 Healthcare 87.45%
2 Industrials 0.73%
3 Technology 0.55%
4 Financials 0.45%
5 Consumer Discretionary 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DYN icon
51
Dyne Therapeutics
DYN
$4.24B
$15.6M 0.23%
+435,653
New +$17.3M
RXRX icon
52
Recursion Pharmaceuticals
RXRX
$1.6B
$15.3M 0.23%
+2,315,000
New +$16.6M
NAMS icon
53
NewAmsterdam Pharma
NAMS
$3.53B
$15M 0.22%
901,750
+32,500
+4% +$562K
VTYX
54
DELISTED
Ventyx Biosciences
VTYX
$14.6M 0.22%
6,715,501
+885,931
+15% +$2.04M
CON
55
Concentra Group Holdings
CON
$4.08B
$14.5M 0.22%
+650,000
New +$15M
ACCD
56
DELISTED
Accolade Inc
ACCD
$13.4M 0.2%
3,475,000
– –
AUTL
57
Autolus Therapeutics
AUTL
$389M
$13.2M 0.2%
3,639,000
– –
FATE icon
58
Fate Therapeutics
FATE
$283M
$12.4M 0.19%
3,555,871
– –
PHR icon
59
Phreesia
PHR
$657M
$12.4M 0.19%
544,448
+352,101
+183% +$8.25M
TNGX icon
60
Tango Therapeutics
TNGX
$4.35B
$11.9M 0.18%
1,540,000
– –
NKTX icon
61
Nkarta
NKTX
$162M
$9.74M 0.15%
2,155,000
-1,644,143
-43% -$9.34M
PRLD icon
62
Prelude Therapeutics
PRLD
$310M
$7.8M 0.12%
3,766,120
-366,880
-9% -$1.7M
ALEC icon
63
Alector
ALEC
$168M
$4.92M 0.07%
1,055,192
-93,134
-8% -$499K
KYTX icon
64
Kyverna Therapeutics
KYTX
$481M
$4.49M 0.07%
918,892
-1,064,108
-54% -$8.2M
CALC icon
65
CalciMedica
CALC
$11.1M
$4.43M 0.07%
1,000,000
– –
INSM icon
66
Insmed
INSM
$22.7B
$3.86M 0.06%
52,861
+41,502
+365% +$3.06M
PRME icon
67
Prime Medicine
PRME
$544M
$3.47M 0.05%
896,960
– –
ANNX icon
68
Annexon
ANNX
$841M
$3.46M 0.05%
583,913
– –
HLVX
69
DELISTED
HilleVax
HLVX
$3.31M 0.05%
1,882,654
-2,121,577
-53% -$5.44M
JBIO
70
Jade Biosciences
JBIO
$1.21B
$2.95M 0.04%
40,332
– –
OMIC
71
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$2.6M 0.04%
166,162
– –
MLAB icon
72
Mesa Laboratories
MLAB
$540M
$2.55M 0.04%
19,664
+16,083
+449% +$1.89M
AIN icon
73
Albany International
AIN
$2.16B
$2.39M 0.04%
26,848
+14,197
+112% +$1.25M
FTRE icon
74
Fortrea Holdings
FTRE
$1.82B
$2.11M 0.03%
+105,470
New +$2.48M
NVDA icon
75
NVIDIA
NVDA
$4.76T
$1.98M 0.03%
16,318
+5,918
+57% +$699K
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q3 2024 Portfolio in Review

As of Q3 2024, Deerfield Management held 678 positions worth $6.69B, up 11% from $6.01B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Deerfield Management withdrew a net $395M in Q3 2024, closing 235 positions and reducing 72 holdings. Its most notable exit was Gilead Sciences, an estimated $102M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 83% a quarter earlier, followed by Industrials and Technology.

Against the trend, Deerfield Management opened a new position in Indivior Pharmaceuticals worth $49.7M.

  • Deerfield Management's largest Q3 2024 buy was Indivior Pharmaceuticals: 5,092,642 shares worth $49.7M.
  • Deerfield Management added most to Neurocrine Biosciences in Q3 2024, an estimated $85.8M increase.
  • Deerfield Management's biggest Q3 2024 reduction was Surgery Partners, cutting an estimated $86.4M.
  • Deerfield Management fully exited Gilead Sciences in Q3 2024, selling an estimated $102M.
  • Deerfield Management's ten largest holdings make up 54% of its $6.69B portfolio in Q3 2024.
  • Deerfield Management opened 246 new positions and closed 235 in Q3 2024.
  • Deerfield Management's portfolio value rose 11% quarter-over-quarter to $6.69B.

Based on Deerfield Management's 13F filing for Q3 2024, filed 14 Nov 2024.